Dr Michelle Bradney is the Chief Executive Officer of Cerulea Clinical Trials, bringing more than two decades of global experience across clinical research, medical affairs, drug and device development, and operational leadership.
Prior to joining Cerulea, Michelle served as Senior Vice President of Medical and Scientific Affairs at Certa Therapeutics, leading global medical affairs, clinical development, and regulatory programs. This included designing clinical trials, authoring protocols and regulatory submissions, and successfully securing FDA and EMA Orphan Drug Designations, as well as FDA IND and Fast Track approvals.
Michelle concurrently held the role of Chief Operating Officer at OccuRx, where she was responsible for company‑wide operations, financial management, governance, and board reporting.
Earlier roles include Head of Medical Affairs at Medical Developments International and Vice President of Medical Affairs at OncoSil Medical, where Michelle led global medical, clinical, pharmacovigilance, and KOL engagement programs across Australia, Europe, the United States, and Asia. Her work directly supported regulatory approvals in major markets, and the expansion of
Michelle began her career in clinical operations with senior leadership roles at Allergan and Sanofi Pasteur, holding regional responsibility for trial conduct, compliance, resourcing, vendor management, SOP implementation, and training across ANZ and APAC regions.
With deep expertise spanning trial design, regulatory strategy, operational execution, and financial governance, Michelle leads Cerulea Clinical Trials Unit with a focus on scalable, high‑quality clinical research delivery and expanding access to innovative trials.